Newsroom | IDEAYA Biosciences

Month Year

News Alerts

Jul 5, 2024

IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that the company plans to issue a...
Jun 28, 2024

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on June 27, 2024, the...
Jun 25, 2024

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer

First-Patient-In (FPI) for Phase 1 combination treatment with IDE397, IDEAYA's MAT2A inhibitor, and Trodelvy®, Gilead's Trop-2 directed antibody-drug conjugate (ADC) The global Phase 1 clinical...
Jun 24, 2024

IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors

Targeting IDE397 Phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable MTAP lung and bladder cancer patients in H2 2024, including RECIST 1.1 clinical efficacy waterfall,...
Jun 3, 2024

IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study

75% eye preservation rate (9 of 12 enucleation patients) ~67% (8 of 12 enucleation patients) observed greater than 30% tumor shrinkage and median tumor shrinkage of 47% by volume change after 6 months

Show per page

News Releases